Skip to main content
main-content

Chronic myeloid leukaemia

05-01-2018 | Oncology | News | Article

approvalsWatch

Nilotinib update acknowledges discontinuation feasibility

Read more on this US FDA decision here

21-12-2017 | Oncology | News | Article

approvalsWatch

FDA approvals announced for advanced RCC, CML

Read more on these decisions here

29-08-2017 | Chronic myeloid leukaemia | News | Article

News in brief

First-line imatinib at 10 years: CML patients achieve ‘close to normal life expectancy’

Findings from the chronic myeloid leukemia IV study suggest that patients in the chronic phase who respond to imatinib have a high likelihood of survival at 10 years.

22-06-2017 | Chronic myeloid leukaemia | Main feed | News

ASCO 2017

Frontline bosutinib ‘an option’ for newly diagnosed CP CML

Study findings suggest that bosutinib could be considered as an alternative to imatinib for first-line tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

Source:

J Clin Oncol 2017; 35: 7002

19-04-2017 | Chronic myeloid leukaemia | News | Article

First-line generic imatinib offers ‘suboptimal efficacy’

For patients undergoing front-line treatment for chronic myeloid leukemia, generic treatment may be less effective than the branded agent, researchers suggest, but treatment efficacy is maintained in patients who switch from a branded to a generic formulation.

Source:

Clin Lymphoma Myeloma Leuk 2017; Advance online publication

12-04-2017 | Chronic myeloid leukaemia | News | Article

Molecular response depth may predict imatinib resistance risk

Study findings suggest that the depth of molecular response to imatinib achieved by a patient with chronic myeloid leukemia may influence the relationship between a fluctuating response to treatment and the likelihood of developing resistance to the tyrosine kinase inhibitor.

Source:

Br J Haematol 2017; Advance online publication

image credits